Clinical and sociodemographic characteristics as predictors for quality of life in transmasculine and transfeminine individuals receiving gender-affirming hormone therapy

被引:1
|
作者
Lad, Saloni U. [1 ]
Sinopoli, Jacob [2 ,3 ]
Khong, Brian [4 ]
Conroy, Britt [3 ,5 ]
Perzynski, Adam T. [6 ]
del Rincon, Juan P. [7 ,8 ]
机构
[1] Cleveland Clin Lerner Coll Med, 9501 Euclid Ave, Cleveland Hts, OH 44195 USA
[2] Chester Summer Scholars Program, Metrohlth Med Syst, 2500 Metrohlth Dr, Cleveland Hts, OH 44109 USA
[3] Case Western Reserve Univ, Cleveland Hts, OH USA
[4] Dept Med, Metrohlth Syst, 2500 Metrohlth Dr, Cleveland Hts, OH 44109 USA
[5] Univ Hosp Cleveland Med Ctr, Dept Urol & Family Med & Community Hlth, 11100 Euclid Ave, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ Metrohlth, Ctr Healthcare Res & Policy, 10900 Euclid Ave, Cleveland, OH 44106 USA
[7] Metrohlth Syst, Dept Med, Cleveland, OH USA
[8] Cleveland Clin, Endocrinol & Metab Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
关键词
Transgender medicine; Social determinants of health; Quality of life; Gender -affirming hormone therapy; ELECTRONIC HEALTH RECORDS; ALCOHOL-CONSUMPTION; TRANSGENDER INDIVIDUALS; FINANCIAL STRAIN; MENTAL-HEALTH; AUDIT-C; RISK; STRESS; RECOMMENDATIONS; METABOLISM;
D O I
10.1016/j.socscimed.2024.116734
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Healthcare systems and providers have increasingly acknowledged the role and impact of social determinants in overall health. However, gender -diverse individuals face persistent health disparities due to their identities. There is limited research on the impact of clinical and sociodemographic characteristics on mood and quality of life (QoL) for transgender (TG) individuals. Our study aims to understand and better elucidate social and clinical characteristics of transmasculine (TM) and transfeminine (TF) individuals and their impact on quality of life and depressive symptoms. In this cross-sectional study, 298 TF and TM individuals on gender -affirming hormone therapy (GAHT) were surveyed about their demographic characteristics (age, gender identity, body mass index (BMI), and education), social needs, mood, and quality of life. Multivariable regression modelling was performed to assess the effect of each variable listed above on three domains of QoL (psychological, environmental, and physical) as well as depressive symptoms. We find that QoL scores are similar between TM and TF individuals, with scores in the psychological domain particularly low in both cohorts. TM individuals report higher rates of stress and restroom avoidance than TF individuals. In particular, psychological well-being (measured by the psychological domain of QoL and depressive symptoms) is significantly associated with increased BMI, financial instability, and stress in TM individuals while for TF individuals, psychological well-being is associated with stress and social integration. These data suggest that social circumstances are key drivers of QoL and psychological well-being among gender -diverse individuals receiving GAHT with specific differences between TF and TM individuals. This information may be utilized by healthcare providers and policymakers to address and improve clinical care and social policies to improve health equity for gender -diverse individuals.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study
    Skewis, Lucas Foster
    Bretherton, Ingrid
    Leemaqz, Shalem Y.
    Zajac, Jeffrey D.
    Cheung, Ada S.
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [22] Risk Assessment and Coronary Artery Calcium Scoring in Transgender and Gender-Diverse Individuals Receiving Gender-Affirming Hormone Therapy
    Duro, Teodor
    McClain, Molly
    Aragon, Kelsea Gallegos
    Casson, Christina
    Choi, Eun Ho Eunice
    Bouchonville, Matthew
    Kapsner, Patricia
    ENDOCRINE PRACTICE, 2023, 29 (04) : 229 - 234
  • [23] Continuation of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Individuals: A Systematic Review
    Gupta, Pranav
    Cunha, Luisa Marin
    Diego, Daniela
    Tangpricha, Vin
    ENDOCRINE PRACTICE, 2024, 30 (12) : 1206 - 1211
  • [24] Breast cancer and gender-affirming hormone therapy for transgender and gender-diverse (TGD) individuals
    -Rake, Elizabeth J. Cathcart
    Ruddy, Kathryn J.
    Tevaarwerk, Amye J.
    Jatoi, Aminah
    MATURITAS, 2024, 181
  • [25] Transgender patients and gender-affirming hormone therapy through the mid-life
    Mehta, Jaya M.
    Kanell, Sarah
    Borowicz, Charlie E. A.
    Fisher, Molly Ainsman
    MATURITAS, 2024, 189
  • [26] The Impact of Gender-affirming Hormone Therapy on Anatomic Structures of the Brain Among Transgender Individuals
    O'LEARY, K. E. R. R. Y. B.
    GARCIA-ALTIERI, M. A. U. R. O. A.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2022, 28 (04) : 328 - 334
  • [27] Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy
    Karalexi, Maria A.
    Frisell, Thomas
    Cnattingius, Sven
    Holmberg, Dag
    Holmberg, Mats
    Kollia, Natasa
    Skalkidou, Alkistis
    Papadopoulos, Fotios C.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (15) : 2017 - 2026
  • [28] Frequency and Characteristics of Postoperative Neuropathy in Individuals on Gender-Affirming Hormone Therapy Undergoing Gender Affirmation Surgery: A Retrospective Cohort Study
    Togioka, Brandon M.
    Harriman, Kevin A.
    Ye, Shangyuan
    Berli, Jens
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [29] Patient-reported and Clinical Outcomes following Gender-affirming Chest Surgery: A Comparison of Binary and Nonbinary Transmasculine Individuals
    Roblee, Cole V.
    Arteaga, Rebecca
    Taritsa, Iulianna
    Ascha, Mona
    Weissman, Joshua P.
    Hackenberger, Paige
    Perez, Megan
    Ellis, Marco
    Jordan, Sumanas W.
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2024, 12 (11)
  • [30] Hormone Concentrations in Transgender Individuals Receiving Gender-Affirming Hormone Therapy: A Longitudinal Retrospective Cohort Study (vol 27, pg 27, 2021)
    Chantrapanichkul, P.
    Stevenson, M. O.
    Suppakitjanusant, P.
    Goodman, M.
    Tangpricha, V
    ENDOCRINE PRACTICE, 2021, 27 (04) : 381 - 381